Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Lymphoma 2Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Neoplasm, Residual 1Mesothelioma 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Hairy Cell 1Leukemia 1Epstein-Barr Virus Infections 1Carcinoma, Transitional Cell 1

Interventions

Peripheral Blood Stem Cell Transplantation 26Rituximab 20Cyclophosphamide 18fludarabine phosphate 17Mycophenolic Acid 16Tacrolimus 14Cyclosporine 14Whole-Body Irradiation 12Filgrastim 11Etoposide 10Radiotherapy 8Methotrexate 8Busulfan 8Therapeutics 7Methylprednisolone 7Antilymphocyte Serum 7Cladribine 6Lenalidomide 5Flow Cytometry 5obinutuzumab 4immunotoxin HA22 4Vorinostat 4Vemurafenib 4Psychiatric Rehabilitation 4Polymerase Chain Reaction 4Ondansetron 4Melphalan 4Granulocyte Colony-Stimulating Factor 4Dexamethasone 4Cord Blood Stem Cell Transplantation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Leukemia, Hairy Cell × Caves × Clear all
NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
175 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡